Ann: Genetic Signatures completes $35m placement, page-4

Given the free kick the company has had over the last two years, it's a terrible indictment of management performance be be trading at levels below the last CR price. Has there been no progress or is it the case of shareholders not appreciating being treated like mushrooms? You also have to wonder why management and the BOD don't see the price at these levels worth dipping into their own pockets while hoping shareholders continue to dip into theirs. And why wouldn't the company be conducting a buy-back given their cash balance and the current market cap? Time to wake up management and look at your performance. The current share price is the scorecard on that.